統合失調症患者におけるRO4917838と抗精神病薬治療の併用に関する研究。

基本情報

NCT ID

NCT00616798

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

323

治験依頼者名

Hoffmann-La Roche

概要

This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent negative or d isorganized thought symptoms. After a 4 week run in period on their current anti psychotic treatment, patients will be randomized to receive placebo 10mg, 30mg, or 60mg of RO4917838 once daily, p.o., as add-on therapy. The anticipated time o n study treatment is \<3 months, and the target sample size is 100-500 individual s.

対象疾患

介入

依頼者（Sponsor）